Blood in the anterior chamber after blunt trauma — risk of rebleed (days 2-5), elevated IOP, and corneal staining; head up, eye shield, sickle screen.
Also known as: hyphema, traumatic hyphema, microhyphema, 8-ball hyphema
Overview
Accumulation of red blood cells in the anterior chamber of the eye, most commonly following blunt or penetrating ocular trauma. Microhyphema refers to circulating red blood cells visible only on slit-lamp examination, without a visible layered blood level.
Epidemiology
Estimated incidence 12-20 per 100,000 per year. Predominantly affects young men; sports, assault, and projectile injuries (paintballs, fireworks, BB guns) are the most common mechanisms. Children are also at risk from blunt trauma. Spontaneous (nontraumatic) hyphema is uncommon and suggests neovascular disease, intraocular tumor (juvenile xanthogranuloma, retinoblastoma), iris vascular anomaly, or bleeding diathesis.
🔒 Free preview limit reached
Keep reading — start your free trial
You've read your 2 free diagnosis previews. Create your free account to unlock the full Traumatic Hyphema outline — plus all 514 diagnoses, 3,500+ board-style questions, flashcards, and an AI tutor. Your 7-day free trial includes everything, and there's no credit card required.
Bleeding disorders (hemophilia, von Willebrand disease)
Sickle cell disease or trait — markedly worsens outcome
Recent intraocular surgery
Iris neovascularization (diabetic retinopathy, central retinal vein occlusion)
Intraocular tumors
Pathophysiology
Blunt trauma transmits a shockwave that abruptly equatorially expands the globe, tearing the iris root, ciliary body, or both (anterior segment angle structures), with associated rupture of the major arterial circle of the iris and/or ciliary body. Blood accumulates in the anterior chamber. Clot retraction and lysis at days 2-5 carry the highest risk of rebleed. Free hemoglobin in the AC and outflow obstruction by red cells and clot can elevate intraocular pressure. Prolonged or recurrent hemorrhage causes corneal endothelial damage and bloodstaining of the cornea.
Clinical presentation
Symptoms
Pain, blurred vision, and history of recent blunt or penetrating eye trauma
Photophobia
Headache, nausea, or vomiting may indicate elevated intraocular pressure
Diplopia or restricted motility suggests orbital fracture or muscle entrapment
Signs / physical exam
Grossly visible blood layering in the anterior chamber when upright
Grade 0: microhyphema only (no layer); Grade I: less than 1/3 of AC; Grade II: 1/3 to 1/2 of AC; Grade III: greater than 1/2 but not total; Grade IV (8-ball or total): entire AC filled
Corneal blood staining in prolonged or repeat hemorrhage
Classic findings
Layered blood in the anterior chamber after blunt trauma, with elevated IOP and reduced acuity.
Differential diagnosis
Microhyphema (without layered blood) — Cells in AC on slit lamp only; same management principles
Anterior uveitis — Cells and flare in AC without red cells; pain, photophobia, often non-traumatic
Spontaneous hyphema from neovascular disease — No trauma history; diabetic retinopathy, vein occlusion, or rubeosis on dilated fundus exam
Endophthalmitis — Pain, vision loss, hypopyon (white not red), recent surgery or penetrating injury
Open globe injury — Distorted pupil, shallow chamber, vitreous prolapse, visible laceration; do NOT measure IOP; protective shield
Traumatic iritis — Cells and flare without significant red cells; ciliary spasm
Diagnostic workup
Diagnostic criteria
Clinical diagnosis by slit-lamp examination demonstrating red blood cells in the anterior chamber after trauma.
Labs
Sickle cell screen (Sickledex) and hemoglobin electrophoresis if African, Caribbean, Mediterranean, Middle Eastern, or South Asian ancestry — sickling in the AC even with trait can elevate IOP dangerously and limit medication options
CBC, PT/INR if anticoagulated or bleeding diathesis suspected
Type and screen if surgery anticipated
Imaging
Slit-lamp examination and measurement of IOP (gentle, after ruling out open globe)
Dilated fundoscopy and B-scan ultrasound if media opacity prevents posterior segment view (and globe is intact) to evaluate for vitreous hemorrhage, retinal detachment, or intraocular foreign body
CT orbits without contrast if orbital fracture, retained foreign body, or open globe is suspected — never MRI if metallic foreign body possible
Gonioscopy is DEFERRED for at least 3-4 weeks to allow stabilization, then performed to assess for angle recession (predisposes to late glaucoma)
Diagnostic algorithm
flowchart TD
A[Blunt eye trauma<br/>+ blood in AC] --> B{Open globe<br/>features?}
B -->|Yes| C[Shield only<br/>NPO<br/>CT orbit<br/>emergent ophtho]
B -->|No| D[Slit lamp + IOP<br/>+ acuity<br/>+ sickle screen]
D --> E[Shield<br/>head up 30-45°<br/>cycloplegic + topical steroid<br/>no NSAIDs/ASA]
E --> F[Daily ophthalmology<br/>x 5-7 days]
F --> G{Rebleed<br/>or IOP elevation?}
G -->|No| H[Outpatient course<br/>gonioscopy at 3-4 wk]
G -->|Yes| I[Add IOP medications<br/>± antifibrinolytics<br/>consider admission]
I --> J{Corneal staining<br/>or refractory IOP?}
J -->|Yes| K[AC washout]
J -->|No| H
Management algorithm for traumatic hyphema.
Treatment
First-line
Protect the eye with a rigid metal or plastic shield (NOT a patch with pressure)
Strict bed rest or limited activity with elevation of the head of bed to 30-45 degrees to promote settling of blood inferiorly and prevent obstruction of the visual axis and trabecular meshwork
Avoid NSAIDs and aspirin (rebleed risk); use acetaminophen for pain
Topical cycloplegic — cyclopentolate 1% or homatropine 5% twice daily — for comfort and to stabilize iris
Topical corticosteroid — prednisolone acetate 1% four times daily — to reduce inflammation
Daily ophthalmology follow-up for the first 5-7 days due to rebleed and IOP risk
Eye shield at night
Hold anticoagulants and antiplatelets if medically safe, in consultation with prescribing clinician
Second-line / adjunct
Topical IOP-lowering therapy if pressure elevated — timolol, brimonidine, dorzolamide; avoid prostaglandin analogues acutely (inflammation) and avoid carbonic anhydrase inhibitors in sickle cell patients (worsen sickling)
Oral aminocaproic acid 50 mg/kg every 4 hours (max 30 g/day) or oral tranexamic acid — antifibrinolytic agents that reduce rebleed risk; their use varies by institution
Surgical evacuation (anterior chamber washout) indicated for: corneal blood staining, total hyphema with IOP >50 for >5 days or >35 for >7 days (sickle: lower thresholds; >25 for >24 hours), or persistent hyphema beyond 9-10 days
Hospital admission for children, sickle patients, non-compliant patients, severe trauma, or grade III-IV hyphemas at many centers
Complications
Rebleeding (typically days 2-5) — increases risk of every other complication
Acutely elevated IOP and secondary glaucoma
Corneal blood staining — long-term reduction of vision
Optic atrophy from sustained IOP elevation
Late-onset glaucoma from angle recession (years later — lifelong monitoring required)
Educational use only. This outline is a study aid for PA students and is not medical advice or a substitute for clinical judgment. FirstPassPA is an independent study tool and is not affiliated with, endorsed by, or sponsored by NCCPA. PANCE® and PANRE® are registered trademarks of the National Commission on Certification of Physician Assistants.